

Genetic testing service deCODEme shutting down in wake of Amgen/deCODE deal

The big biotech news of the day is the \$415 million sale of deCODE Genetics to Amgen. Coverage of the deal is everywhere, including a [typically excellent overview](#) from Matthew Herper of *Forbes*.

Meanwhile, it's quite likely that the sale to Amgen will usher in the final chapter of deCODE's long-running direct-to-consumer (DTC) genetic testing business, [deCODEme](#). deCODEme's sole product – the [deCODEme Complete Scan](#) – covers 47 conditions and traits and retails for a whopping \$1,100.

Update 12/12: As predicted, Amgen has now confirmed that deCODEme will be shutting down. An [Amgen spokesperson confirmed to *Pharmacogenomics Reporter*](#) that “Amgen does not intend to continue offering genomic screening tests to the public and healthcare providers. This is not a core part of Amgen's business interest in Decode...Employees and resources focused on this area will be realigned with other priorities and projects.”

View the original article here: [Implications of Amgen/deCODE Deal for Genetic Testing Consumers](#)